For years, longevity has been one of technology's most ambitious promises. Billions of dollars have flowed into companies trying to understand, and eventually modify, the biological mechanisms of ageing.
In 2026 something important is changing. The field is moving out of laboratories, animal studies and billionaire-backed moonshots and into human clinical trials.
That does not mean science has learned how to stop ageing. Far from it. It does mean that some of the boldest ideas in longevity research have finally reached the stage where they can be tested in people.
Retro Biosciences moves deeper into human testing
Retro Biosciences, the longevity company backed by Sam Altman, has taken its experimental oral therapy RTR242 into Phase I testing. The company was founded around an extraordinarily ambitious objective: adding ten healthy years to human life.
RTR242 targets autophagy, the recycling process through which cells break down and reuse damaged components. Ageing impairs that process, particularly the work of lysosomes, the structures at the centre of cellular cleanup. Retro is investigating whether restoring parts of this machinery could eventually have therapeutic value in age-related disease, beginning with neurodegeneration.
The study is randomised, double-blind and placebo-controlled, runs in healthy volunteers at an early-phase clinical unit in Adelaide, and has since widened as researchers move to higher doses. Alongside standard safety measures it tracks exploratory biomarkers tied to autophagy and lysosomal biology, which gives the company its first look at whether its hypotheses produce measurable signals in people. Retro has set out the wider programme in its own pipeline update.
This remains an early safety trial. There is no clinical evidence that RTR242 extends human lifespan, and its effect on neurodegenerative disease is still unproven. The significance lies in the transition itself. Longevity biology has entered the clinic.
Epigenetic reprogramming reaches humans
Another milestone arrived in June 2026, when Life Biosciences announced that the first participant had been dosed in a Phase I trial of ER-100, an experimental therapy for optic neuropathies including open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy.
The science behind it is unusually bold. ER-100 uses the controlled expression of three transcription factors, OCT4, SOX2 and KLF4, to shift gene expression in the eye back toward more youthful patterns. It is delivered by injection into the eye, and it is the first time a partial epigenetic reprogramming therapy has been given to a human being.
Researchers have long been drawn to the possibility that some age-related changes inside a cell could be reversed without erasing the identity of that cell. Moving the idea into human testing does not prove that biological ageing can be reversed. It allows the field to start answering a more useful question: can these mechanisms be turned into medicine that is safe and effective?
How do we know whether any of it works?
This leads to the hardest problem in the industry. Human beings live too long for conventional lifespan studies to give quick answers. If researchers want to know whether an intervention extends healthy life, waiting several decades for participants to age is not a workable plan.
The field therefore needs biomarkers that show, in reasonable time, whether an intervention is genuinely affecting biological ageing. A major analysis published in Nature Medicine in August 2026 examined exactly that. Researchers harmonised data from 51 longitudinal human intervention studies and tested 16 prominent epigenetic clocks alongside more than a hundred DNA methylation biomarkers.
Two findings stand out. Lifestyle change, meaning diet combined with exercise, and several established drugs, among them metformin, semaglutide and anti-TNF therapies, consistently lowered epigenetic age. Over-the-counter supplements largely did not. Newer clocks also outperformed the older ones, and biomarkers moved more in people who were ill than in people who were healthy. A companion piece, Putting epigenetic aging clocks on trial, sets out what still has to be proven before regulators will treat such a clock as a surrogate endpoint.
The caution matters. A clock that says someone has become biologically younger is not by itself proof that the person will live longer or avoid disease.
The industry needs evidence, not noise
That distinction is the whole story of the next few years. Longevity has attracted extraordinary attention from founders, investors and wealthy consumers, and with it a fast-growing market of supplements, diagnostics, clinics and treatments. Scientific evidence does not move at the speed of consumer enthusiasm.
An August 2026 editorial in Nature Medicine, Anti-aging interventions need less hype and more clinical evidence, made the point plainly. The journal noted that while the biology of ageing offers no shortage of promising targets, from inflammation and cell senescence to epigenetic drift and inadequate autophagy, data showing real clinical benefit in humans remain sparse.
This may be the governing principle of longevity's next phase. The field does not need smaller ambitions. It needs stronger evidence.
Why investors are paying attention
For investors and family offices, longevity sits at the intersection of several powerful trends. Populations are ageing. Healthcare spending is rising. AI is accelerating biological research and drug discovery. Genomics, cellular engineering and regenerative medicine keep opening therapeutic doors that did not exist a decade ago. And wealthy consumers are willing to spend heavily on healthspan.
The potential market is enormous. So is the risk. Many companies will fail, and technologies that look transformative in the laboratory often do not survive contact with clinical testing. That is normal in biotechnology. The skill lies in telling scientific progress apart from narrative.
From lifespan to healthspan
The most important shift in longevity may be conceptual rather than technical. The goal is no longer simply to help people live longer. It is to extend the years spent in good health: delaying the diseases of ageing and preserving cognitive, metabolic and physical function for longer.
If longevity biotechnology succeeds, its greatest effect may not be a dramatic extension of maximum human lifespan. It may be something more practical and, in the end, more transformative. It may change how we age.
The first human trials will not settle that question. They mark the moment when longevity's biggest promises finally have to meet clinical reality.
Longevity is one of the themes on the programme at THE LIVE Barcelona, 26-28 October 2026, where investors, family offices and founders examine where private capital meets the science of healthy life. Meet the speakers or secure your place.
Sources and further reading
- Retro Biosciences: pipeline and clinical programme
- Longevity.Technology: Retro Bio commences first-in-human trial
- Life Biosciences: first patient dosed with ER-100
- Nature Medicine: responsiveness of epigenetic ageing biomarkers to longevity interventions in humans
- Nature Medicine: putting epigenetic aging clocks on trial
- Nature Medicine editorial: anti-aging interventions need less hype and more clinical evidence